Dyslipidaemia in the Web of Multiple Chronic Conditions
A new therapy for lipid management. The role of PCSK9i.
Secondary prevention and high risk cardiovascular patients are recommended high dose statin therapy according to national guidelines. What is the evidence around new class of therapy PSCK9i in the reduction of LDL cholesterol and how are they tolerated in the real world?